Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 51 | 2024 | 11074 | 4.890 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2024 | 3256 | 1.050 |
Why?
|
Tissue Array Analysis | 3 | 2021 | 553 | 1.000 |
Why?
|
Prostate | 8 | 2023 | 1773 | 0.970 |
Why?
|
Serine Endopeptidases | 5 | 2023 | 1073 | 0.920 |
Why?
|
Organic Anion Transporters | 1 | 2024 | 100 | 0.900 |
Why?
|
Neoplasms, Bone Tissue | 1 | 2020 | 7 | 0.760 |
Why?
|
Squalene Monooxygenase | 2 | 2017 | 11 | 0.730 |
Why?
|
PTEN Phosphohydrolase | 3 | 2020 | 1143 | 0.730 |
Why?
|
Cholesterol | 4 | 2022 | 2911 | 0.730 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2023 | 1581 | 0.670 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 179 | 0.660 |
Why?
|
Radiation, Ionizing | 1 | 2019 | 258 | 0.640 |
Why?
|
Aspirin | 3 | 2018 | 3282 | 0.610 |
Why?
|
Sterol O-Acyltransferase | 1 | 2017 | 27 | 0.610 |
Why?
|
DNA Repair | 4 | 2023 | 2046 | 0.610 |
Why?
|
NADH, NADPH Oxidoreductases | 1 | 2017 | 93 | 0.600 |
Why?
|
Gangrene | 1 | 2016 | 82 | 0.550 |
Why?
|
Nonprescription Drugs | 1 | 2016 | 116 | 0.520 |
Why?
|
Male | 65 | 2024 | 350027 | 0.510 |
Why?
|
Receptors, LDL | 1 | 2017 | 475 | 0.500 |
Why?
|
BRCA1 Protein | 2 | 2023 | 1149 | 0.490 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2938 | 0.480 |
Why?
|
Genes, Tumor Suppressor | 1 | 2019 | 1097 | 0.480 |
Why?
|
Oncogenes | 1 | 2020 | 1265 | 0.470 |
Why?
|
Follow-Up Studies | 21 | 2024 | 39045 | 0.460 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1071 | 0.430 |
Why?
|
Foot | 1 | 2016 | 528 | 0.420 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 2948 | 0.420 |
Why?
|
Metformin | 2 | 2016 | 835 | 0.410 |
Why?
|
Radiation Dosage | 1 | 2019 | 1928 | 0.380 |
Why?
|
Humans | 73 | 2024 | 744220 | 0.350 |
Why?
|
Prescription Drugs | 1 | 2016 | 595 | 0.340 |
Why?
|
Prospective Studies | 12 | 2024 | 53280 | 0.340 |
Why?
|
Genetic Variation | 3 | 2020 | 6546 | 0.330 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2279 | 0.320 |
Why?
|
Phthalazines | 2 | 2020 | 363 | 0.320 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2023 | 8426 | 0.310 |
Why?
|
Prognosis | 10 | 2023 | 29050 | 0.270 |
Why?
|
Age Factors | 1 | 2022 | 18367 | 0.270 |
Why?
|
Prostate-Specific Antigen | 4 | 2022 | 2478 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9960 | 0.240 |
Why?
|
Genomics | 1 | 2020 | 5722 | 0.240 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2023 | 30 | 0.230 |
Why?
|
Dietary Supplements | 1 | 2016 | 3297 | 0.230 |
Why?
|
Phenotype | 2 | 2020 | 16365 | 0.220 |
Why?
|
Aged | 19 | 2024 | 163253 | 0.220 |
Why?
|
Prostatitis | 1 | 2022 | 102 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3132 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3239 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2023 | 318 | 0.200 |
Why?
|
BRCA2 Protein | 3 | 2022 | 794 | 0.200 |
Why?
|
RNA Editing | 1 | 2022 | 148 | 0.200 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13668 | 0.200 |
Why?
|
Diabetes Mellitus | 2 | 2020 | 5755 | 0.200 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2022 | 106 | 0.190 |
Why?
|
Gabexate | 1 | 2020 | 12 | 0.190 |
Why?
|
Stathmin | 1 | 2020 | 71 | 0.190 |
Why?
|
Androgen Antagonists | 3 | 2024 | 1361 | 0.190 |
Why?
|
Middle Aged | 18 | 2020 | 213367 | 0.180 |
Why?
|
Piperazines | 2 | 2020 | 2491 | 0.180 |
Why?
|
p300-CBP Transcription Factors | 1 | 2021 | 147 | 0.180 |
Why?
|
Arm | 1 | 2022 | 590 | 0.170 |
Why?
|
Paraffin Embedding | 1 | 2020 | 299 | 0.170 |
Why?
|
Guanidines | 1 | 2020 | 191 | 0.170 |
Why?
|
Epidemiologic Studies | 1 | 2023 | 676 | 0.170 |
Why?
|
Androgens | 2 | 2024 | 1279 | 0.170 |
Why?
|
Esters | 1 | 2020 | 210 | 0.170 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 514 | 0.160 |
Why?
|
Neoplasm Staging | 4 | 2021 | 11007 | 0.160 |
Why?
|
Signal Transduction | 2 | 2020 | 23404 | 0.160 |
Why?
|
src-Family Kinases | 1 | 2020 | 551 | 0.160 |
Why?
|
Orchiectomy | 1 | 2020 | 466 | 0.150 |
Why?
|
Dyslexia, Acquired | 1 | 2017 | 14 | 0.150 |
Why?
|
Environment | 1 | 2023 | 1124 | 0.150 |
Why?
|
Trypsinogen | 1 | 2016 | 86 | 0.140 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2020 | 671 | 0.140 |
Why?
|
Adult | 15 | 2024 | 214035 | 0.140 |
Why?
|
Cryoglobulins | 1 | 2016 | 59 | 0.140 |
Why?
|
Reproducibility of Results | 3 | 2024 | 19907 | 0.140 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2505 | 0.140 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20123 | 0.140 |
Why?
|
Aneuploidy | 1 | 2019 | 530 | 0.130 |
Why?
|
Cryoglobulinemia | 1 | 2016 | 87 | 0.130 |
Why?
|
Incidence | 4 | 2023 | 20945 | 0.130 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2022 | 933 | 0.130 |
Why?
|
Candidiasis | 1 | 2018 | 366 | 0.130 |
Why?
|
Plasmapheresis | 1 | 2016 | 212 | 0.130 |
Why?
|
DNA Copy Number Variations | 2 | 2022 | 1940 | 0.130 |
Why?
|
Risk Factors | 8 | 2023 | 72280 | 0.130 |
Why?
|
Toes | 1 | 2016 | 207 | 0.130 |
Why?
|
Histocompatibility | 1 | 2016 | 330 | 0.130 |
Why?
|
Gene Expression Profiling | 2 | 2023 | 9438 | 0.130 |
Why?
|
Cost of Illness | 1 | 2023 | 1859 | 0.110 |
Why?
|
Cohort Studies | 5 | 2024 | 40559 | 0.110 |
Why?
|
Epigenomics | 1 | 2018 | 903 | 0.110 |
Why?
|
Disease Progression | 2 | 2020 | 13280 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4841 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1061 | 0.110 |
Why?
|
Chromosome Aberrations | 1 | 2019 | 1814 | 0.110 |
Why?
|
Population Surveillance | 1 | 2023 | 2616 | 0.110 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1831 | 0.100 |
Why?
|
Neonatal Screening | 1 | 2016 | 591 | 0.100 |
Why?
|
Uropathogenic Escherichia coli | 1 | 2011 | 6 | 0.100 |
Why?
|
Biopsy | 1 | 2023 | 6757 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2023 | 1797 | 0.100 |
Why?
|
Software | 2 | 2024 | 4442 | 0.100 |
Why?
|
Immunohistochemistry | 2 | 2021 | 11368 | 0.090 |
Why?
|
Self Report | 1 | 2021 | 3558 | 0.090 |
Why?
|
Blastocystis Infections | 1 | 2010 | 16 | 0.090 |
Why?
|
Blastocystis | 1 | 2010 | 19 | 0.090 |
Why?
|
Intestinal Diseases, Parasitic | 1 | 2010 | 66 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2183 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1518 | 0.090 |
Why?
|
Genotype | 1 | 2024 | 12956 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6535 | 0.080 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2702 | 0.080 |
Why?
|
Aged, 80 and over | 5 | 2020 | 57768 | 0.080 |
Why?
|
Influenza, Human | 1 | 2020 | 1480 | 0.080 |
Why?
|
Urticaria | 1 | 2010 | 150 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2021 | 5169 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5319 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3158 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3703 | 0.080 |
Why?
|
Cystic Fibrosis | 1 | 2016 | 1178 | 0.080 |
Why?
|
Escherichia coli Infections | 1 | 2011 | 532 | 0.070 |
Why?
|
Mutation | 5 | 2024 | 29784 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2022 | 15525 | 0.070 |
Why?
|
United States | 4 | 2023 | 69867 | 0.070 |
Why?
|
Exercise | 2 | 2023 | 5615 | 0.070 |
Why?
|
Cell Line, Tumor | 2 | 2021 | 16687 | 0.070 |
Why?
|
Neoplasms | 3 | 2024 | 21672 | 0.070 |
Why?
|
Survival Rate | 4 | 2020 | 12781 | 0.070 |
Why?
|
Electronic Health Records | 1 | 2022 | 4463 | 0.060 |
Why?
|
Vitamin D | 1 | 2019 | 3222 | 0.060 |
Why?
|
Urinary Tract Infections | 1 | 2011 | 788 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2022 | 20817 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2023 | 12264 | 0.060 |
Why?
|
Hematopoiesis | 2 | 2024 | 2069 | 0.060 |
Why?
|
Retrospective Studies | 4 | 2022 | 77426 | 0.060 |
Why?
|
Residence Characteristics | 2 | 2023 | 2050 | 0.060 |
Why?
|
Survival Analysis | 1 | 2016 | 10250 | 0.060 |
Why?
|
Risk | 1 | 2015 | 9685 | 0.060 |
Why?
|
Genome | 2 | 2022 | 1808 | 0.050 |
Why?
|
Marital Status | 1 | 2024 | 437 | 0.050 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2022 | 74 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2022 | 17449 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 12075 | 0.050 |
Why?
|
Young Adult | 5 | 2020 | 56436 | 0.050 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2022 | 298 | 0.050 |
Why?
|
Spain | 1 | 2022 | 465 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2018 | 6352 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3584 | 0.050 |
Why?
|
Algorithms | 1 | 2020 | 13885 | 0.040 |
Why?
|
Histone Demethylases | 1 | 2022 | 321 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8387 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 631 | 0.040 |
Why?
|
Genetic Fitness | 1 | 2020 | 121 | 0.040 |
Why?
|
Chromosomes | 1 | 2022 | 596 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 665 | 0.040 |
Why?
|
Female | 9 | 2022 | 380197 | 0.040 |
Why?
|
Zinc | 1 | 2022 | 683 | 0.040 |
Why?
|
Glycolysis | 1 | 2022 | 826 | 0.040 |
Why?
|
Genomic Instability | 1 | 2022 | 695 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2016 | 5442 | 0.040 |
Why?
|
Lysine | 1 | 2022 | 1008 | 0.040 |
Why?
|
Registries | 2 | 2024 | 8090 | 0.040 |
Why?
|
Genetics, Population | 1 | 2022 | 934 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2020 | 705 | 0.040 |
Why?
|
beta-Glucans | 1 | 2018 | 123 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3339 | 0.040 |
Why?
|
Drug Synergism | 1 | 2020 | 1791 | 0.040 |
Why?
|
Chemistry Techniques, Analytical | 1 | 2016 | 49 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2019 | 618 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2022 | 1057 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2022 | 12355 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2020 | 63119 | 0.030 |
Why?
|
Selection, Genetic | 1 | 2020 | 914 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1787 | 0.030 |
Why?
|
Hemianopsia | 1 | 2017 | 122 | 0.030 |
Why?
|
Candida albicans | 1 | 2018 | 394 | 0.030 |
Why?
|
Writing | 1 | 2017 | 206 | 0.030 |
Why?
|
Actins | 1 | 2022 | 2121 | 0.030 |
Why?
|
Adolescent | 2 | 2020 | 85759 | 0.030 |
Why?
|
Social Class | 1 | 2023 | 1999 | 0.030 |
Why?
|
Social Support | 1 | 2024 | 2117 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3689 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2022 | 2013 | 0.030 |
Why?
|
Prostatectomy | 1 | 2022 | 1887 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 2503 | 0.030 |
Why?
|
Reading | 1 | 2017 | 558 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6313 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3557 | 0.030 |
Why?
|
Trans-Activators | 1 | 2022 | 2924 | 0.030 |
Why?
|
Medical Oncology | 1 | 2024 | 2265 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2749 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3598 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2018 | 3144 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3461 | 0.020 |
Why?
|
Pattern Recognition, Visual | 1 | 2017 | 824 | 0.020 |
Why?
|
Paromomycin | 1 | 2010 | 10 | 0.020 |
Why?
|
Life Style | 1 | 2022 | 3835 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2942 | 0.020 |
Why?
|
HLA Antigens | 1 | 2016 | 1382 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6485 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2023 | 3385 | 0.020 |
Why?
|
Risk Assessment | 2 | 2022 | 23337 | 0.020 |
Why?
|
Phosphorylation | 1 | 2021 | 8437 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7784 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2022 | 5021 | 0.020 |
Why?
|
Metronidazole | 1 | 2010 | 217 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2020 | 25618 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3086 | 0.020 |
Why?
|
Insulin | 1 | 2022 | 6583 | 0.020 |
Why?
|
Virulence Factors | 1 | 2011 | 509 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2023 | 9647 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13409 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15070 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10480 | 0.020 |
Why?
|
Infant | 2 | 2020 | 35129 | 0.020 |
Why?
|
Apoptosis | 1 | 2020 | 9728 | 0.020 |
Why?
|
Escherichia coli Proteins | 1 | 2011 | 1053 | 0.010 |
Why?
|
Models, Biological | 1 | 2020 | 9582 | 0.010 |
Why?
|
Child, Preschool | 2 | 2020 | 40992 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 814 | 0.010 |
Why?
|
Cell Line | 1 | 2018 | 15999 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10634 | 0.010 |
Why?
|
Drug Resistance, Bacterial | 1 | 2011 | 1036 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2016 | 2957 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81178 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2010 | 972 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14726 | 0.010 |
Why?
|
Animals | 3 | 2020 | 168788 | 0.010 |
Why?
|
Child | 2 | 2020 | 77679 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8343 | 0.010 |
Why?
|
Chronic Disease | 1 | 2010 | 9147 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7179 | 0.010 |
Why?
|
Brain | 1 | 2017 | 26413 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 35423 | 0.010 |
Why?
|